SPDR Series Trust - State Street SPDR S&P Biotech ETF
ARCAXBI short interest utilization hits 92.46%, near its 52-week high of 100%. Shares available to borrow remain tight relative to the estimated 110% short interest of free float. Cost to borrow has declined 63% over the past month to 1.92%, easing pressure on short positions despite elevated utilization levels.
Snapshot as of 7 May 2026
No long-form analysis yet for XBI. Pulse alerts and the live data picture are available on ORTEX.
Open XBI on ORTEX →Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for XBI — free to start on ORTEX.
Sign up for free →Open XBI on ORTEX